Click here to see it on AdPharm

AdPharm is the largest online pharmaceutical advertising gallery. It is subscription-based with various subscriptions plans available here.

Click here to see it on AdPharm

AdPharm is the largest online pharmaceutical advertising gallery. It is subscription-based with various subscriptions plans available here.

Click here to see it on AdPharm

AdPharm is the largest online pharmaceutical advertising gallery. It is subscription-based with various subscriptions plans available here.

Click here to see it on AdPharm

AdPharm is the largest online pharmaceutical advertising gallery. It is subscription-based with various subscriptions plans available here.

Click on thumbnail to view the full-size ad on AdPharm

Back to school
Demonstrated efficacy with duration that spans multiple life settings.
8:30 AM – School time
5 PM – Activity time
8 PM – Homework/family time

Brand name: Vyvanse
Generic name/category: Lisdexamfetamine, Amphetamines
Company: Shire
Country/Market: USA, North America
Indication(s)/use: attention-deficit hyperactivity disorder (ADHD)
Target: Healthcare Professionals (HCP)
Tagline: For the treatment of ADHD
Medium: Print ad
Size/duration: single-page
Publication/Aired: Contemporary Pediatrics – September 2009

To see all of this brand’s ads on AdPharm, click here

To prevent and potentially reverse many of the symptoms of Type 1 Gaucher Disease
Cerezyme leads the way

Proven efficacy and safety for over 14 years

Brand name: Cerezyme
Generic name/category: Imiglucerase for injection
Company: Genzyme
Country/Market: USA, North America
Indication(s)/use: Gaucher’s Disease
Target: Healthcare Professionals (HCP)
Tagline: Leads the way
Medium: Print ad
Size/duration: single-page
Publication/Aired: Blood – September 17, 2009

Voici Abilify, indiqu?© dans le traitement de la schizophr?©nie.
Parce que les sympt??mes n?©gatifs font aussi partie de la route.

Une att?©nuation des sympt??mes positifs et n?©gatifs a ?©t?© d?©montr?©e avec Abilify.

Nouveau Abilify.

Here's Abilify, indicated for the treatment of schizophrenia.
Because negative symptoms are also part of the road.

New Abilify.

Aripiprazole (marketed as Abilify, Abilify Discmelt; also known as BMS 337039, OPC-14597, and APZ) was approved by the Food and Drug Administration (FDA) on November 15, 2002 for the treatment of schizophrenia, the sixth atypical antipsychotic medication of its kind. More recently, it received FDA approval for the treatment of acute manic and mixed episodes associated with bipolar disorder, and as an adjunct for the treatment of major depressive disorder. Aripiprazole was developed by Otsuka in Japan; in the U.S., Otsuka America markets the drug jointly with Bristol-Myers Squibb.

More on Wikipedia

Brand name: Abilify
Generic name/category: Aripiprazole, Atypical antipsychotics, Piperazines
Company: Bristol-Myers Squibb (BMS)
Country/Market: Canada, North America
Indication(s)/use: Schizophrenia
Target: Healthcare Professionals (HCP)
Medium: Print ad
Size/duration: double-page spread
Publication/Aired: Le M?©decin du Qu?©bec – September 2009

To see all of this brand's ads on AdPharm, click here
0 views
Sep 09, 2009

Visit AdPharm.net for more pharmaceutical ads